Oct 03,2023

Insulet Announces CFO Transition

Insulet today announced that Wayde McMillan has decided to step down from his role as Executive Vice President, Chief Financial Officer and Treasurer, effective October 20, 2023, to join 3M’s healthcare business, which the company plans to spin off at the end of the year or early 2024. Lauren Budden, Group Vice President, Chief Accounting Officer and Controller, will assume the additional responsibilities of Interim CFO and Treasurer until a permanent successor is appointed.

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023 TOP STORY

Phillips-Medisize Teams with GlucoModicum to Develop an Innovative Needle-Free Continuous Glucose Monitor

Phillips-Medisize, a Molex company, and a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, invitro diagnostic and medtech devices, has teamed with GlucoModicum, an innovative medtech company based in Finland, to design and eventually commercialize a proprietary non-invasive, wearable device that removes technology and patient-care roadblocks to continuous glucose monitoring (CGM). In seeking a more convenient, rapid and gentle CGM alternative, GlucoModicum discovered that magnetohydrodynamic (MHD) technology could be used to apply a small amount of energy directly to interstitial fluid to drive it to the surface of the skin for quick and easy extraction of a glucose sample. GlucoModicum sought an experienced contract development and manufacturing organization (CDMO) to assist in realizing their vision for a new device, called Talisman. The device is not yet FDA approved and does not have the CE mark.

COLLABORATION PARTNERSHIP

#r&d

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023

DarioHealth to Host Investor Day on The Rise of Digital Health

DarioHealth announced that it will host an in-person investor day in New York at the offices of Sullivan & Worcester LLP located at 1633 Broadway, 32nd floor, on October 17, 2023 at 11:00 AM ET. The event will feature digital health industry leaders, including Arnaud Robert, respected technology expert and former Head of Digital for Sanofi, Disney and Nike, and Felix Lee, U.S. Digital Healthcare Medical Head, Sanofi U.S., who will discuss the rise of digital health and the clinical research shaping its future.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 04,2023

Lilly Announces Leadership Transitions

Eli Lilly and Company today announced changes to its executive leadership team. Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company. Patrik Jonsson will assume leadership of Lilly Diabetes and Obesity as executive vice president and president, effective January 1, 2024, in addition to his current responsibility as executive vice president and president of Lilly USA. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories, will take on the additional role of president of Lilly Immunology from Jonsson.

View Analyst & Ambassador Comments
Go to original news
Oct 04,2023

Tubeless Insulin Pump Market is estimated to be US$ 8.85 billion by 2032

According to the research publisher, tubeless insulin pump market accounted for US$ 1.31 billion in 2022 and is estimated to be US$ 8.85 billion by 2032 and is anticipated to register a CAGR of 21.3%. Tubeless Insulin Pumps are small, discrete and lightweight in nature also called as insulin patch pumps used by type 1 diabetes patients.

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Oct 04,2023 TOP STORY

Welldoc Expands Chronic Care Digital Health Platform to Include Weight Management

Welldoc announced the expansion of its platform to support weight management. Welldoc’s comprehensive chronic care platform now provides multi-condition support across prediabetes, diabetes, hypertension, heart failure and weight management, along with integrated mental wellbeing and sleep apnea support. Welldoc’s weight management solution is currently available to all customers and will be launching in early 2024 with two of the leading health care companies in the U.S. As part of Welldoc’s total health approach to chronic care, AI-driven, personalized digital coaching is available 24/7 to help individuals navigate weight management whether they are just beginning their weight management journey with lifestyle changes or are prescribed a GLP-1 medication. “Weight management is a natural extension of Welldoc’s award-winning chronic care platform which has offered best-in-class behavioral support related to nutrition and activity for years. Welldoc is now addressing the evolving needs of our users with an evidence-based weight management program that seamlessly integrates into existing care plans,” said Catherine Brown, Vice President, Clinical Services at Welldoc.

PRODUCT

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 26,2023 TOP STORY

Dexcom and SocialDiabetes Join Forces to Make Diabetes Management More Accessible

Dexcom and SocialDiabetes have joined forces to help people with diabetes improve their control over the disease. Through this international agreement, Dexcom device data is integrated into the SocialDiabetes platform along with other relevant health data such as insulin dosing data recorded by Smartpens, nutritional information and physical activity collected from various wearables; providing both patients and professionals with a complete metabolic map.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 28,2023 TOP STORY

Lark Health Expands Weight Management Program to Support Guided GLP-1 Care Delivery

Lark Health announced today the expansion of its personalized weight management solutions to include an enhanced set of services designed to support employers and health plans through the unprecedented employee demand for GLP-1 medications. Lark’s approach to GLP-1 management includes a tailored combination of responsible clinical screening and prescribing, ongoing clinical management, and industry-leading behavior change coaching that’s available 24/7. As part of this approach, Lark will now offer three new programs – the Healthy Weight program, GLP-1 Companion program, and Clinician-Guided Step Therapy program. Healthy Weight program is designed to be replacement to the to more expensive GLP-1 solutions with behaviora change support for lifestyle modification. GLP-1 Companion Program for those taking GLP-1 medications includes side effect management, medication adherence support, and clinical escalations. Clinician-Guided Step Therapy provides access to end-to-end clinician-led therapy, offering insurance navigation, prescription management, lab monitoring, and ongoing management to ensure continuity of care.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 28,2023 TOP STORY

Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes

Better Therapeutics announced it has completed the enrollment of 1,000 participants across two studies as part of its ongoing clinical program to evaluate the long-term effectiveness of AspyreRxTM (formerly BT-001). AspyreRx received FDA authorization in July 2023 as the first PDT to deliver Cognitive Behavioral Therapy (CBT) to treat adults with type 2 diabetes (T2D). Better Therapeutics' ongoing clinical studies are designed to assess the long-term effectiveness of AspyreRx in diverse populations, as measured by change in HbA1c, and safety, as measured by severity and frequency of adverse events. The impact on medication use and healthcare utilization one year after beginning treatment with AspyreRx will also be evaluated, along with an advanced understanding of patient engagement patterns in a real-world setting. Depending on adequate power, Better Therapeutics plans to share initial 6-month data by the end of 2023. This initial readout is expected to be followed by additional data releases in 2024.

CLINICAL STUDY

#dtx

View Analyst & Ambassador Comments
Go to original news
Sep 28,2023

Insulet to Announce Third Quarter 2023 Financial Results on November 2, 2023

Insulet Corporation announced plans to release its financial results for the third quarter of 2023 on November 2, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES